Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescriptions increased from 2018 to 2025, while MBS use decreased beginning in 2023, according to a research letter published online March 4 in JAMA Surgery.
Continue Reading this article here
